Use of Complementary Medicine in SARS-CoV-2 and MERS-CoV: a Narrative Review
Novelty in Biomedicine,
Vol. 10 No. 2 (2022),
Severe acute respiration syndrome coronavirus 2 (SARS-CoV-2) is characterized by severe cytokine storm syndrome following inflammation. SARS-CoV-2 is the 7th coronavirus that causes infection in human bodies; SARS-CoV, MERS-CoV, and SARS-CoV-2 can purpose severe diseases. SARS-CoV-2 at once interacts with angiotensin-converting enzyme 2 (ACE-2) receptors inside the body and causes respiratory problems. Interestingly, complementary medicines and herbal drugs affect the expression of IgE and IgG antibodies and improve the immune system; for that reason, complementary medicine could be beneficial for infectious diseases like SARS-COV-2. In this review, we assessed some related articles to evaluate the effect of complementary medicine on SARS-COV2 and MERS-COV.
- COVID-19, Coronavirus, SARS-COV-2, MERS-COV
How to Cite
World Health Organization Severe acute respiratory syndrome (SARS) multi-country outbreak—update 4. Outbreak reported March 19, 2003. Available from: URL: http://www.who.int/csr/don/2003_03_19/en/
Centers for Disease Control and Prevention Outbreak of severe acute respiratory syndrome—worldwide, 2003. [Erratum in: MMWR Morb Mortal Wkly Rep 2003;52:284] MMWR Morb Mortal Wkly Rep. 2003;52:226–8
World Health Organization A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet. 2003;361:1730–3 10.1016/S0140-6736(03)13376-4
Acute respiratory syndrome China, Hong Kong Special Administrative Region of China, and Viet Nam. Wkly Epidemiol Rec. 2003;78:73–74.
World Health Organization Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Revised September 26, 2003. Available from: URL: http://www.who.int/csr/sars/country/table2003_09_23/en/
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–66.
Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–76.
Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–25.
WHO Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS) http://www.who.int/csr/sarscountry/en/ (accessed April 25, 2003)
Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Infez Med. 2020;28(suppl 1):6-17.
Abduljalil JM, Abduljalil BM. Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. New microbes and new infections. 2020;35:100672.
Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Holzmann T, Schmidt B, Hanses F. Epidemiology of SARS-CoV-2. Infection. 2020;1-7.
Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature microbiology. 2020;5(11):1403-7.
Fattahi Z, Mohseni M, Jalalvand K, Aghakhani Moghadam F, Ghaziasadi A, Keshavarzi F, et al. SARS‐CoV‐2 outbreak in Iran; the dynamics of the epidemic and evidence on two independent introductions. Transboundary and emerging diseases. 2021 Apr 9.
Pourhossein B, Dabbagh A, Fazeli MJJoC, Anesthesia M. Insights into the SARS-CoV2 Outbreak; the great global challenge: A mini review. 2020;5(1):23-6.
Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med. 2003;349:2431–41.
Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R, et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. MedRxiv. 2020 Jan 1.
Morris G, Bortolasci CC, Puri BK, Olive L, Marx W, O'Neil A, et al. The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. Life sciences. 2020:118166.
Mulangu S, Dodd LE, Davey Jr RT, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. 2019;381(24):2293-303.
Pan H, Peto R, Karim QA. Repurposed antiviral drugs for COVID-19–interim WHO solidarity trial results. medRxiv 2020. Google Scholar.
MULANGU, Sabue, et al. A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine, 20evi19, 381.24: 2293-2303.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. 2020;30(3):269-71.
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020;56(1):105949.
Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. In Seminars in arthritis and rheumatism 1993 Oct 1 (Vol. 23, No. 2, pp. 82-91). WB Saunders.
Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. Journal of Pharmacology and Experimental Therapeutics. 2018;365(3):447-59.
Nugraha RV, Ridwansyah H, Ghozali M, Khairani AF, Atik NJE-BC, Medicine A. Traditional herbal medicine candidates as complementary treatments for COVID-19: a review of their mechanisms, pros and cons. 2020;2020.
Boyd JE, Lanius RA, McKinnon MC. Mindfulness-based treatments for posttraumatic stress disorder: a review of the treatment literature and neurobiological evidence. Journal of Psychiatry & Neuroscience. 2018 Jan.
Nidich S, Mills PJ, Rainforth M, Heppner P, Schneider RH, Rosenthal NE, et al. Non-trauma-focused meditation versus exposure therapy in veterans with post-traumatic stress disorder: a randomised controlled trial. The Lancet Psychiatry. 2018;5(12):975-86.
Sullivan MB, Erb M, Schmalzl L, Moonaz S, Noggle Taylor J, Porges SW. Yoga therapy and polyvagal theory: The convergence of traditional wisdom and contemporary neuroscience for self-regulation and resilience. Frontiers in Human Neuroscience. 2018;12:67.
Bushell WC. Serum factor that restores youthful function to apparently senescent stem cells is identified by recently developed expert decision tree-guided bioinformatics program. In: Control and Regulation of Stem Cells. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2008.
d'Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al. Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. 2020;7:389.
León O, Menéndez S, Merino N, Castillo R, Sam S, Pérez L, et al. Ozone oxidative preconditioning: a protection against cellular damage by free radicals. 1998;7(4):289-94.
Clavo B, Santana-Rodríguez N, Llontop P, Gutiérrez D, Suárez G, López L, et al. Ozone therapy as adjuvant for cancer treatment: is further research warranted? 2018;2018.
Clavo B, Rodríguez-Esparragón F, Rodríguez-Abreu D, Martínez-Sánchez G, Llontop P, Aguiar-Bujanda D, et al. Modulation of oxidative stress by ozone therapy in the prevention and treatment of chemotherapy-induced toxicity: review and prospects. 2019;8(12):588.
Mawsouf M, Tanbouli T, Viebahn-Hänsler RJOs, engineering. Ozone Therapy in Patients with Viral Hepatitis C: Ten Years' Experience. 2012;34(6):451-8.
Murray BK, Ohmine S, Tomer DP, Jensen KJ, Johnson FB, Kirsi JJ, et al. Virion disruption by ozone-mediated reactive oxygen species. 2008;153(1):74-7.
Bocci V. Ozone A new medical drug: Springer; 2005.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. 2020;94:91-5.
Cho H-J, Jeong Y-J, Park K-K, Park Y-Y, Chung I-K, Lee K-G, et al. Bee venom suppresses PMA-mediated MMP-9 gene activation via JNK/p38 and NF-κB-dependent mechanisms. 2010;127(3):662-8.
Baek YH, Huh JE, Lee JD, Park DSJBr. Antinociceptive effect and the mechanism of bee venom acupuncture (Apipuncture) on inflammatory pain in the rat model of collagen-induced arthritis: Mediation by α2-Adrenoceptors. 2006;1073:305-10.
Choi J, Jeon C, Lee JH, Jang JU, Quan FS, Lee K, et al. Suppressive effects of bee venom acupuncture on paclitaxel-induced neuropathic pain in rats: mediation by spinal α2-adrenergic receptor. 2017;9(11):351.
Bostanci N, Belibasakis GN. Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen. FEMS microbiology letters. 2012;333(1):1-9.
Reusken CB, Farag EA, Jonges M, Godeke GJ, El-Sayed AM, Pas SD, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar. Euro Surveill. 2014;19(23).
Haagmans BL, Brand JMA, Raj VS, Volz A, Wohlsein P, Smits SL, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351(6268):77–81.
Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis. 2016.
Mohd HA, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir. Virol J. 2016;13:87.
Liya G, Yuguang W, Jian L, Huaiping Y, Xue H, Jianwei H, et al. Studies on viral pneumonia related to novel coronavirus SARS‐CoV‐2, SARS‐CoV, and MERS‐CoV: a literature review. Apmis. 2020;28(6):423-32.
Ramadan N, Shaib H. Middle East respiratory syndrome coronavirus (MERS-CoV): A review. Germs. 2019;9(1):35.
de Wilde AH, Jochmans D, Posthuma CC. Screening of an FDA‐approved compound library identifies four small‐molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875‐84.
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS‐CoV. Nat Commun. 2020;11(1):222.
Middle W.H.O. East respiratory syndrome coronavirus (MERS-CoV) - update: 2 DECEMBER 2013 2013. http://www.who.int/csr/don/2013_12_02/en/
Al-Tawfiq J.A., Auwaerter PG. Healthcare-associated infections: the hallmark of the Middle East respiratory syndrome coronavirus (MERS-CoV) with review of the literature. J Hosp Infect. 2018 doi: 10.1016/j.jhin.2018.05.021. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Al-Tawfiq J.A., Memish Z.A. Drivers of MERS-CoV transmission: what do we know? Expert Rev Respir Med. 2016;10:331–8.
Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM. A family cluster of middle east respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis. 2013;17:e668–e672. doi: 10.1016/j.ijid.2013.07.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah A, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368:2487–94.
Memish ZA, Cotten M, Watson SJ, Kellam P, Zumla A, Alhakeem RF. Community case clusters of Middle East respiratory syndrome coronavirus in hafr Al-batin, kingdom of Saudi Arabia: a descriptive genomic study. Int J Infect Dis. 2014;23:63–8.
Chan JF, Yao Y, Yeung ML. Treatment with lopinavir/ritonavir or interferon‐beta1b improves outcome of MERS‐CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904‐13.
Spanakis N, Tsiodras S, Haagmans BL. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. 2014;44(6):528‐32.
Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon‐alpha for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455‐9.
Jia W. Retrospectivestudy of the effect of glucocorticosteroids on the treatment of severe acute respiratory syndrome 2006 [D]. Sun Yat-sen University; 2006. http://www.wanfangdata.com.cn/details/detail.do?_type=degree&id=Y1014520.
Wang P, Li M, Shi Y, Wang S, Liu G. Evaluating the effects of different treatments on severe acute respiratory syndrome. Shanxi Med J. 2005;34:270–2.
Wang G, Li N, Wu Y, Xie G, Lin J, Huang C, et al. The Cox regression analysis on the use of corticosteroids in the treatment of SARS. Natl Med J China. 2004;84:1073–78.
Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129:1441–52.
Hwang JH, Cho HJ, Im HB, Jung YS, Choi SJ, Han D. Complementary and alternative medicine use among outpatients during the 2015 MERS outbreak in South Korea: a cross-sectional study. BMC complementary medicine and therapies. 2020;20:1-0.
Gezici S, Sekeroglu N. Novel SARS-CoV-2 and COVID-2019 Outbreak: Current Perspectives on Plant-Based Antiviral Agents and Complementary Therapy.
Kasozi KI, Niedbała G, Alqarni M, Zirintunda G, Ssempijja F, Musinguzi SP, et al. Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections. Frontiers in public health. 2020;8:755.
d'Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al. Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Frontiers in medicine. 2020;7:389.
Alkharaan H, Bayati S, Hellström C, Olsson A, Lindahl K, Bogdanovic G, et al. Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. medRxiv. 2021 Jan 1.
Nikose SS, Nikose D, Kekatpure A, Awasthi A, Jain S, Kumbhre V. Does complementary and alternative therapy work for SARS-CoV-2 (COVID-19)?
- Abstract Viewed: 38 times
- pdf Downloaded: 21 times